{"product_id":"resmed-swot-analysis","title":"ResMed SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssess ResMed's Strategic Position with Investor-Focused Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eResMed's leadership in sleep apnea and respiratory care, supported by recurring software and device revenue, global reach, and a differentiated product portfolio, shapes both its competitive strengths and key risk exposures. This SWOT analysis helps investors evaluate operational resilience, regulatory and reimbursement sensitivity, innovation execution, and long-term value drivers; purchase the full report for a detailed, research-backed review and editable Excel tools for informed decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Share in Sleep Disordered Breathing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed holds roughly 60%-65% share of the global CPAP\/APAP market in 2025 after Philips' long absence, creating an installed base exceeding 20 million devices that generates recurring consumable revenue-masks, tubing, filters-estimated at ~$1.2 billion annually.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Digital Health and Informatics Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed shifted from devices to digital health with AirView and myAir, powering over 18 million cloud‑connectable devices as of Dec 2025 and capturing trillions of sleep and therapy data points to raise adherence; in FY2025 software and SaaS offerings contributed about 28% of revenue (~$1.9B), driving better clinical outcomes and lowering hospitalization risk; integrated workflows create strong switching costs for providers tied into its ecosystem.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Financial Performance and High Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed posts gross margins around 60% and operating margins near 20%, well above the med-tech median; these high margins reflect pricing power in sleep and respiratory care. As of Q3 2025, ResMed held about $2.8 billion in cash and generated trailing‑12‑month free cash flow of roughly $1.1 billion, funding R\u0026amp;D spend near $460 million YTD. This strong cash flow cushions macro risk and supports disciplined M\u0026amp;A and capital allocation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property and Innovation Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed holds over 4,500 granted patents and thousands pending across flow generators, masks, and respiratory algorithms, creating a strong barrier to entry for competitors.\u003c\/p\u003e\n\u003cp\u003eResMed invested about $460 million in R\u0026amp;D in FY2024, keeping it ahead on mask comfort and device quietness-key drivers of patient compliance and adherence.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 ResMed's latest devices cut size and weight by ~18% and added low-power Bluetooth\/5G connectivity, setting new benchmarks for portability and remote monitoring.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4,500+ granted patents\u003c\/li\u003e\n\u003cli\u003e$460M R\u0026amp;D FY2024\u003c\/li\u003e\n\u003cli\u003e~18% smaller\/lighter by 2025\u003c\/li\u003e\n\u003cli\u003eBluetooth\/5G connectivity, enhanced algorithms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Brand Recognition and Clinical Trust\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed is seen by sleep physicians and respiratory therapists as the gold standard for clinical efficacy and device reliability, backed by 200+ peer-reviewed studies through 2025 that drive clinical adoption.\u003c\/p\u003e\n\u003cp\u003eThat deep evidence base and brand trust make it hard for low-cost rivals to displace ResMed, supporting higher pricing and faster uptake for new respiratory products.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e200+ peer-reviewed studies (through 2025)\u003c\/li\u003e\n\u003cli\u003ePremium pricing sustained vs low-cost rivals\u003c\/li\u003e\n\u003cli\u003eStronger point-of-care patient preference\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: CPAP Leader-65% Share, $1.9B SaaS, \u0026gt;20M Devices, $1.1B FCF\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed dominates CPAP with ~60-65% share in 2025, \u0026gt;20M installed devices and recurring consumables ≈$1.2B\/yr; software\/SaaS ~28% revenue (~$1.9B FY2025) with \u0026gt;18M cloud devices; gross margin ≈60%, TTM FCF ~$1.1B, cash ~$2.8B; 4,500+ patents, $460M R\u0026amp;D FY2024, 200+ peer‑reviewed studies.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPAP share (2025)\u003c\/td\u003e\n\u003ctd\u003e60-65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstalled devices\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables rev\u003c\/td\u003e\n\u003ctd\u003e$1.2B\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware\/SaaS rev FY2025\u003c\/td\u003e\n\u003ctd\u003e$1.9B (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM FCF\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$2.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e4,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2024\u003c\/td\u003e\n\u003ctd\u003e$460M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer‑reviewed studies\u003c\/td\u003e\n\u003ctd\u003e200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of ResMed, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and future growth potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise ResMed SWOT matrix for rapid strategic alignment, ideal for executives seeking a clear snapshot of competitive positioning and product-market strengths.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Revenue Concentration in Sleep Apnea\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite growing digital health and ventilator lines, ResMed still earns roughly 70% of FY2025 revenue from sleep-disordered breathing and CPAP-related products (FY2025 revenue $4.4B; sleep segment ≈ $3.1B), leaving the company exposed if guidelines, reimbursement, or diagnostic trends shift.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium Pricing Strategy in Price-Sensitive Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eResMed's premium pricing limits adoption in price-sensitive markets; in 2024 roughly 40% of global sleep apnea device demand came from emerging markets where average selling prices are 30-50% lower, per industry reports. As payers tighten budgets-US Medicare device reimbursements flat in 2023 and many EU health systems cutting procurement-ResMed risks losing entry-level share to low-cost rivals who undercut prices by 20-40%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Reimbursement Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eResMed depends heavily on Medicare and private insurers for reimbursement; a 10% cut in durable medical equipment (DME) rates would shave millions from provider purchasing power and could reduce ResMed device volumes.\u003c\/p\u003e\n\u003cp\u003eIn 2024 Medicare DME spending fell 2.1% year-over-year, and any further downward rate adjustments would hit revenues tied to CPAP and ventilator sales.\u003c\/p\u003e\n\u003cp\u003eShifts to value-based care-projected to cover \u0026gt;40% of Medicare beneficiaries by late 2025-pressure fee-for-service equipment sales and force ResMed to prove outcomes to sustain pricing. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Complexity of SaaS Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed's acquisitions of Brightree (2016) and MatrixCare (2018) broadened its out-of-hospital SaaS footprint, but integrating disparate platforms raises operational complexity and costs - ResMed reported 2024 R\u0026amp;D and SG\u0026amp;A of US$1.2bn and US$1.8bn respectively, showing scale but integration burden.\u003c\/p\u003e\n\u003cp\u003eSoftware update friction or poor cross-platform compatibility can drive churn in a competitive healthcare IT market where median annual SaaS churn ~10% (2023), risking subscription revenue growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMultiple platforms need distinct skills\u003c\/li\u003e\n\u003cli\u003e2024 SG\u0026amp;A\/R\u0026amp;D: US$3.0bn total\u003c\/li\u003e\n\u003cli\u003eHealthcare SaaS median churn ~10% (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong Product Development and Regulatory Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe medical device sector's heavy regulation makes ResMed's R\u0026amp;D slow and capital‑heavy; ResMed spent $418.8 million on R\u0026amp;D in FY2025 (ended Sept 30, 2025), so approval timelines materially affect cash deployment and returns.\u003c\/p\u003e\n\u003cp\u003eGlobal regulatory complexity delays launches-CE, FDA, and PMDA filings can stagger releases by months-hindering simultaneous rollouts across major markets.\u003c\/p\u003e\n\u003cp\u003eLong lead times limit ResMed's ability to match fast consumer-tech shifts in sleep and respiratory care devices, risking feature gaps versus agile digital entrants.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D spend FY2025: $418.8M\u003c\/li\u003e\n\u003cli\u003eRegulatory stagger: months per region\u003c\/li\u003e\n\u003cli\u003eRisk: slower response to consumer-tech trends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSleep-focused revenue (70%) and Medicare exposure threaten growth as costs rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh dependence on sleep\/CPAP: ~70% of FY2025 revenue (FY2025 revenue $4.4B; sleep ≈ $3.1B) risks exposure to guideline\/reimbursement shifts. Premium pricing limits share in emerging markets (~40% demand; ASPs 30-50% lower), enabling low-cost rivals to undercut by 20-40%. Heavy reliance on Medicare\/DME means reimbursement cuts (Medicare DME spending -2.1% in 2024) would hit volumes. Integration of Brightree\/MatrixCare raises SG\u0026amp;A\/R\u0026amp;D burden (FY2025 SG\u0026amp;A+R\u0026amp;D = US$3.0B) and SaaS churn risk (~10%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2025 revenue\u003c\/td\u003e\n\u003ctd\u003e$4.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSleep segment\u003c\/td\u003e\n\u003ctd\u003e$3.1B (~70%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D FY2025\u003c\/td\u003e\n\u003ctd\u003e$418.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A+R\u0026amp;D FY2025\u003c\/td\u003e\n\u003ctd\u003e$3.0B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare DME change 2024\u003c\/td\u003e\n\u003ctd\u003e-2.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHealthcare SaaS churn (median 2023)\u003c\/td\u003e\n\u003ctd\u003e~10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eResMed SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is the same file included in your download. Buy now to unlock the complete, editable version with full detail and structured insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpansion into Undiagnosed Global Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEstimates indicate ~936 million adults worldwide have obstructive sleep apnea, most undiagnosed, creating a huge patient pool ResMed can target.\u003c\/p\u003e\n\u003cp\u003eResMed can grow by funding awareness and simplified at-home screening tech; converting 1% of that pool equals ~9.4 million new patients and meaningful recurring mask and device revenue.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, Asia and Latin America are key: MENA\/Asia-Pacific countries showed double-digit device volume growth in 2023-24, offering long-term expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Integration with GLP-1 Weight Loss Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rapid adoption of GLP-1 weight-loss drugs (US prescriptions rose ~1,200% from 2020-2024; Ozempic\/ Wegovy combined revenue ~ $18.5B in 2024) lets ResMed position its CPAP and ventilator devices as complementary, not replaced. Partnering with pharma firms could enable integrated weight and sleep-tracking platforms for patients losing 5-15% body weight on average, preserving respiratory therapy continuity. This holistic metabolic-respiratory offering may open referral channels from obesity clinics and add new patient cohorts, supporting durable device utilization and recurring software revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth in Out-of-Hospital SaaS Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe global shift to aging in place and home care-65+ population rising 34% from 2015-2025 in OECD countries-boosts demand for ResMed's out‑of‑hospital SaaS; in 2024 ResMed reported software revenue of $1.6B, up ~20% YoY, showing traction.\u003c\/p\u003e\n\u003cp\u003eExpanding SaaS into home health and hospice management could target the $150B US post‑acute market (2024 estimate), letting ResMed capture higher ARPU and share.\u003c\/p\u003e\n\u003cp\u003eSaaS adds high‑margin, recurring revenue: ResMed's software gross margins exceed 70%, making it less cyclical than device sales and improving revenue stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Driven Personalized Medicine and Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpadvancements in ai let resmed build predictive algorithms that flag patients at risk of non potentially reducing therapy dropouts cloud data million monitored globally as fuels these models.\u003e\n\u003cpby late ai diagnostics could cut time-to-treatment by weeks-studies show triage can shorten diagnostic time therapy starts and improving outcomes.\u003e\n\u003cpusing its large real dataset to tune personalized therapy adjustments mask fit adherence prompts gives resmed a clear precision edge and could raise device utilization recurring revenue.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e20M+ patients monitored (2024)\u003c\/li\u003e\n\u003cli\u003e30-50% faster diagnosis with AI (studies)\u003c\/li\u003e\n\u003cli\u003eHigher utilization → recurring revenue growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pusing\u003e\u003c\/pby\u003e\u003c\/padvancements\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversification into Adjacent Respiratory Chronic Conditions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResMed can leverage its flow-generator tech to enter COPD and asthma markets, where global COPD prevalence hit 391 million in 2019 and respiratory device market projected to reach $44.6B by 2025; expanding ventilator and oxygen concentrator lines reduces sleep-apnea revenue concentration (sleep devices ~60% of 2024 revenue). \u003c\/p\u003e\n\u003cp\u003eStrategic acquisitions or in-house non-invasive ventilation (NIV) development-using R\u0026amp;D and M\u0026amp;A-could position ResMed as a total respiratory-health provider and capture higher-margin chronic-care services. \u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal COPD cases 391M (2019)\u003c\/li\u003e\n\u003cli\u003eRespiratory device market ~$44.6B by 2025\u003c\/li\u003e\n\u003cli\u003eSleep devices ≈60% of ResMed 2024 revenue\u003c\/li\u003e\n\u003cli\u003eNIV M\u0026amp;A accelerates market entry\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResMed: $1.6B SaaS, 20M+ monitored, 9.4M new OSA patients opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLarge undiagnosed OSA pool (~936M adults), 1% conversion ≈9.4M new patients; 20M+ patients monitored (2024) enable SaaS\/AI upsell; software revenue $1.6B (2024), \u0026gt;70% gross margin boosts recurring revenue; Asia\/LatAm double‑digit device growth and COPD market ($44.6B by 2025) let ResMed diversify via NIV and pharma\/weight-loss partnerships.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUndiagnosed OSA\u003c\/td\u003e\n\u003ctd\u003e~936M adults\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1% conversion\u003c\/td\u003e\n\u003ctd\u003e≈9.4M patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients monitored (2024)\u003c\/td\u003e\n\u003ctd\u003e20M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$1.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware gross margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRespiratory market (2025)\u003c\/td\u003e\n\u003ctd\u003e$44.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Impact of Pharmaceutical Interventions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe rapid uptake of GLP-1 weight-loss drugs (over 13M US prescriptions by mid-2024) could shrink obstructive sleep apnea prevalence; if 10-20% of CPAP candidates achieve sustained weight loss, ResMed's CPAP TAM might contract by ~5-15% over 10 years, pressuring device revenue (ResMed reported $3.2B device revenue FY2024). Investors flagged this risk in late-2025 guidance uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResurgence of Major Competitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe anticipated full-scale return of Philips to the global sleep-apnea market raises competitive intensity for new patient starts, with Philips regaining share after its 2021-2023 recall and projected 2025 device relaunches. As rivals clear regulatory hurdles and introduce next-gen devices, ResMed could face aggressive pricing and marketing, risking margin compression: ResMed gross margin was 58.7% in FY2025, so a 200-300bps hit would cut operating income materially. Increased customer acquisition costs may follow as competitors pursue reimbursements and provider contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCybersecurity and Data Privacy Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a leader in cloud-connected sleep and respiratory devices, ResMed faces high-profile cyberattack risk; healthcare breaches averaged 4.35 million records exposed in 2023, raising stakes for medical device makers.\u003c\/p\u003e\n\u003cp\u003eA breach of patient health data could trigger class actions, HIPAA fines (up to $1.9M per violation category) and steep remediation costs; MedTech incident costs averaged $11.45M per breach in 2023.\u003c\/p\u003e\n\u003cp\u003eMaintaining zero-trust security, regular FDA cybersecurity guidance compliance, and SOC 2 controls drives rising R\u0026amp;D and IT spend; ResMed reported $1.2B R\u0026amp;D+SG\u0026amp;A in FY2025, a portion for security.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Economic and Currency Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eResMed's global footprint makes revenue and margins sensitive to FX swings; in FY2024 about 38% of revenue was outside the US, so a 5% USD strength can cut reported sales materially.\u003c\/p\u003e\n\u003cp\u003eEconomic slowdowns in Europe or China could trim provider CAPEX and delay device replacements-global sleep-apnea device demand grew ~6% in 2023 but is cyclical.\u003c\/p\u003e\n\u003cp\u003eGeopolitical supply shocks raised component costs in 2022-24, pushing gross margin pressure; a 10-15% rise in semiconductor prices would hit device costs significantly.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~38% revenue outside US (FY2024)\u003c\/li\u003e\n\u003cli\u003e5% USD swing materially affects reported sales\u003c\/li\u003e\n\u003cli\u003eDevice demand ~6% growth in 2023-cyclical\u003c\/li\u003e\n\u003cli\u003e10-15% semiconductor price rises boost unit costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShifts in Diagnostic Technology and Home Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe rise of home sleep testing (HST) and consumer wearables is shifting patient entry into the clinical funnel, with HST use up ~35% from 2019-2023 and wearables market revenue reaching $36.9B in 2024, raising diagnosis volume but enabling tech entrants.\u003c\/p\u003e\n\u003cp\u003eIf wearables reach clinical-grade accuracy, sleep labs and device-makers like ResMed (2024 revenue $4.9B for sleep + respiratory) face margin pressure and potential device-displacement risk.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHST use +35% (2019-2023)\u003c\/li\u003e\n\u003cli\u003eWearables market $36.9B (2024)\u003c\/li\u003e\n\u003cli\u003eResMed sleep\/respiratory revenue $4.9B (2024)\u003c\/li\u003e\n\u003cli\u003eClinical-grade wearables could cut lab referrals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP‑1 threat, pricing \u0026amp; cyber risks imperil ResMed margins and global revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGLP-1 uptake (13M US scripts by mid-2024) could cut CPAP TAM 5-15% over 10 years; ResMed device rev $3.2B FY2024. Philips' 2025 relaunch raises pricing pressure; 200-300bps gross-margin risk from competitive pricing (ResMed GM 58.7% FY2025). Cyber breaches (health avg 4.35M records 2023) risk $11.45M avg remediation and HIPAA fines. FX (38% rev outside US FY2024) and component cost shocks (10-15% chip price rise) add margin risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP-1 US scripts (mid-2024)\u003c\/td\u003e\n\u003ctd\u003e13M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResMed device rev\u003c\/td\u003e\n\u003ctd\u003e$3.2B FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e58.7% FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecords exposed (healthcare)\u003c\/td\u003e\n\u003ctd\u003e4.35M 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg breach cost\u003c\/td\u003e\n\u003ctd\u003e$11.45M 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue outside US\u003c\/td\u003e\n\u003ctd\u003e38% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChip price shock\u003c\/td\u003e\n\u003ctd\u003e+10-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53667864117590,"sku":"resmed-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/resmed-swot-analysis.webp?v=1778896417","url":"https:\/\/balancedscorecardexamples.com\/products\/resmed-swot-analysis","provider":"Balanced Scorecard","version":"1.0","type":"link"}